Skip to main content

Table 2 Main Preoperative Characteristics of the Study Population.

From: Thrombotic gene polymorphisms and postoperative outcome after coronary artery bypass graft surgery

  Study population
(n = 220)
FVL 1691 G/G
(n = 196)
FVL 1691 G/A
(n = 24)
p value* PT 20210 G/G
(n = 212)
PT 20210 G/A
(n = 8)
p value** ACE I/I
and
ACE I/D
(n = 124)
ACE D/D+
(n = 57)
p value***
Age (yrs), mean ± SD 62.5 ± 10.2 62.5 ± 10.2 62.3 ± 10.6 NS 62.7 ± 10.2 57.6 ± 8.5 NS 62.0 ± 9.7 63.2 ± 10.5 NS
Female sex, n (%) 58 (26.4) 54 (24.6) 4 (16.7) NS 56 (26.4) 2 (25) NS 29 (23.4) 13 (22.8) NS
Body surface area (m2), mean ± SD 1.8 ± 0.2 1.8 ± 0.2 1.8 ± 0.1 NS 1.8 ± 0.2 1.8 ± 0.2 NS 1.8 ± 0.2 1.79 ± 0.14 NS
Hypertension, n (%) 89 (40.5) 80 (40.8) 9 (37.5) NS 88 (41.5) 1 (12.5) NS 46 (37.1) 34 (59.7) 0.004
Diabetes, n (%) 118 (53.6) 107 (54.6) 11 (45.8) NS 113 (53.3) 5 (62.5) NS 68 (54.8) 29 (50.9) NS
Hypercholesterolemia, n (%) 94 (42.7) 83 (42.4) 11 (45.8) NS 92 (43.4) 2 (25) NS 59 (47.6) 28 (49.1) NS
Smoking, n (%) 122 (55.5) 107 (54.6) 15 (62.5) NS 122 (57.6) 2 (25) NS 66 (53.2) 35 (61.4) NS
Previous stroke, n (%) 3 (1.4) 3 (1.5) 0 NS 3 (1.4) 0 NS 1 (0.8) 1 (1.8) NS
Peripheral arterial disease, n (%) 25 (11.4) 22 (11.2) 3 (12.5) NS 24 (11.3) 1 (12.5) NS 10 (8.1) 13 (22.8) 0.006
Previous hospital admission for MI, n (%) 52 (23.6) 43 (21.9) 9 (37.5) NS 51 (24.1) 1 (12.5) NS 26 (21.0) 23 (40.4) 0.007
COPD, n (%) 32 (14.6) 28 (12.7) 4 (16.7) NS 32 (15.1) 0 NS 17 (13.7) 12 (21.1) NS
Creatinine > 2.3 mg/dL, n (%) 7 (3.2) 5 (2.6) 2 (8.3) NS 6 (2.8) 1 (12.5) NS 1 (0.8) 2 (3.5) NS
Catheter lab emergency, n (%) 5 (2.6) 5 (2.6) 0 NS 4 (1.9) 1 (12.5) NS 0 2 (3.5) NS
Number of diseased coronary arteries, n (%) 2.4 ± 0.7 2.4 ± 0.7 2.4 ± 0.7 NS 2.4 ± 0.7 2.4 ± 0.9 NS 2.4 ± 0.71 2.5 ± 0.7 NS
Totally Occluded Coronary Arteries, n (%) 0.1 ± 0.3 0.1 ± 0.2 0.46 ± 0.7 < 0.001 0.08 ± 0.3 0.3 ± 0.5 < 0.001 0.1 ± 0.35 0.1 ± 0.3 NS
Left ventricular aneurysm, n (%) 10 (4.6) 5 (2.6) 5 (20.8) 0.002 9 (4.3) 1 (12.5) NS 8 (6.5) 1 (1.8) NS
Intracardiac thrombus, n (%) 2 (0.9) 2 (0.9) 0 NS 2 (0.9) 0 NS 1 (0.8) 1 (1.8) NS
Ischemic mitral regurgitation, n (%) 19 (8.6) 16 (8.2) 3 (12.5) NS 17 (8.0) 2 (25) NS 15 (12.1) 4 (7.0) NS
LVEF (%) mean ± SD 52.8 ± 9.9 53.3 ± 9.9 49.3 ± 9.0 NS 52.7 ± 10.0 55.9 ± 4.9 NS 53.6 ± 10.1 52.84 ± 10.1 NS
EuroScore, mean ± SD 1.3 ± 1.3 1.9 ± 1.5 1.9 ± 1.5 NS 2.0 ± 1.5 1.9 ± 1.5 NS 1.85 ± 1.5 1.93 ± 1.4 NS
  1. Values are mean ± SD or percentage of patients, FVL indicates factor V Leiden; PT 20210, prothrombin/factor II; ACE-ins/del, angiotensin-converting enzyme gene insertion/deletion polymorphism; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; NS, Non-significant. The study population of ACE D/D genotype consisted of 181 patients.
  2. * FVL 1691G/G compared with FVL 1691 G/A polymorphism; ** PT 20210 G/G compared with PT 20210 G/A polymorphism; *** ACE I/I and ACE I/D group compared with ACE D/D polymorphism group.